Sigyn Therapeutics completes animal study for Sigyn Therapy; safe and well-tolerated in 8 subjects

Sigyn Therapeutics, Inc.

Eight porcine subjects received up to six-hour treatments; no serious adverse events reported.
One treatment halted due to clot from procedural deviation; no serious outcome observed.
Company plans to submit IDE to FDA to support initiation of human clinical studies.
In vitro studies validated broad-spectrum removal of endotoxins, cytokines, and viral pathogens.
CEO states milestone advances clinical vision for sepsis treatment.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.